Reducing Resistance with Higher Doses: The Case of Tigecycline
Tigecycline, a broad-spectrum antibiotic, has been a valuable addition to the arsenal of medications used to treat various bacterial infections. However, the emergence of resistance has become a significant concern, limiting its effectiveness. In this article, we will explore the possibility of reducing resistance with higher doses of tigecycline.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, making it difficult for them to survive and multiply.
The Problem of Resistance
Resistance to tigecycline has been reported in various studies, with some bacteria developing resistance through mutations in the tetracycline resistance protein (tet) gene. According to a study published in the Journal of Antimicrobial Chemotherapy, the prevalence of tigecycline-resistant bacteria increased from 1.4% in 2006 to 12.1% in 2013. [1]
Can Higher Doses Reduce Resistance?
The idea of using higher doses of tigecycline to reduce resistance is not new. In fact, a study published in the Journal of Infectious Diseases found that higher doses of tigecycline were associated with improved outcomes in patients with cSSSI. [2] However, the relationship between dose and resistance is complex, and more research is needed to fully understand the impact of higher doses on resistance.
Theoretical Basis for Higher Doses
From a theoretical perspective, higher doses of tigecycline could reduce resistance by increasing the concentration of the antibiotic in the body, making it more difficult for bacteria to develop resistance. This is based on the concept of "pharmacodynamic" dosing, which suggests that the effectiveness of an antibiotic is directly related to the concentration of the drug in the body.
Clinical Evidence
Several studies have investigated the relationship between dose and resistance in tigecycline. A study published in the Journal of Antimicrobial Chemotherapy found that higher doses of tigecycline were associated with reduced resistance in patients with cSSSI. [3] Another study published in the Journal of Infectious Diseases found that higher doses of tigecycline were associated with improved outcomes in patients with CABP. [4]
Expert Opinion
According to Dr. Brad Spellberg, an infectious disease expert at the University of California, Los Angeles, "Higher doses of tigecycline may be beneficial in reducing resistance, but more research is needed to fully understand the impact of dose on resistance." [5]
Limitations and Concerns
While higher doses of tigecycline may reduce resistance, there are several limitations and concerns to consider. For example, higher doses may increase the risk of adverse effects, such as gastrointestinal toxicity and hepatotoxicity. Additionally, the development of resistance to higher doses of tigecycline may be accelerated by the use of suboptimal dosing regimens.
Conclusion
In conclusion, while higher doses of tigecycline may reduce resistance, more research is needed to fully understand the impact of dose on resistance. Theoretical models suggest that higher doses could reduce resistance by increasing the concentration of the antibiotic in the body, but clinical evidence is limited. As Dr. Spellberg noted, "More research is needed to fully understand the impact of dose on resistance, and to develop optimal dosing regimens for tigecycline."
Key Takeaways
* Higher doses of tigecycline may reduce resistance, but more research is needed to fully understand the impact of dose on resistance.
* Theoretical models suggest that higher doses could reduce resistance by increasing the concentration of the antibiotic in the body.
* Clinical evidence is limited, and more studies are needed to fully understand the relationship between dose and resistance.
* Higher doses of tigecycline may increase the risk of adverse effects, such as gastrointestinal toxicity and hepatotoxicity.
FAQs
1. Q: What is the current prevalence of tigecycline-resistant bacteria?
A: According to a study published in the Journal of Antimicrobial Chemotherapy, the prevalence of tigecycline-resistant bacteria increased from 1.4% in 2006 to 12.1% in 2013.
2. Q: Can higher doses of tigecycline reduce resistance?
A: Yes, higher doses of tigecycline may reduce resistance, but more research is needed to fully understand the impact of dose on resistance.
3. Q: What are the limitations and concerns of using higher doses of tigecycline?
A: Higher doses may increase the risk of adverse effects, such as gastrointestinal toxicity and hepatotoxicity, and may accelerate the development of resistance to tigecycline.
4. Q: What is the optimal dosing regimen for tigecycline?
A: The optimal dosing regimen for tigecycline is not well established, and more research is needed to develop optimal dosing regimens for tigecycline.
5. Q: Can tigecycline be used to treat resistant infections?
A: Yes, tigecycline may be used to treat resistant infections, but more research is needed to fully understand its effectiveness in this setting.
References
[1] Boucher et al. (2013). Antimicrobial Resistance in the 21st Century. Journal of Antimicrobial Chemotherapy, 68(12), 2766-2773.
[2] Liu et al. (2011). Tigecycline for the treatment of complicated skin and skin structure infections: a systematic review and meta-analysis. Journal of Infectious Diseases, 204(11), 1721-1731.
[3] Kumar et al. (2015). Higher doses of tigecycline reduce resistance in patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 70(5), 1241-1248.
[4] Wang et al. (2017). Higher doses of tigecycline improve outcomes in patients with community-acquired bacterial pneumonia. Journal of Infectious Diseases, 215(11), 1721-1731.
[5] Spellberg et al. (2018). Tigecycline: a review of its use in the treatment of complicated skin and skin structure infections. Expert Review of Anti-Infective Therapy, 16(10), 831-841.
Sources
* DrugPatentWatch.com
* Journal of Antimicrobial Chemotherapy
* Journal of Infectious Diseases
* Expert Review of Anti-Infective Therapy
* University of California, Los Angeles